Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, Odile Beyne-Rauzy, Moshe Mittelman, Petra Muus, Stephen D. Nimer, Eva Hellström-Lindberg, Bayard L. Powell, Agnes Guerci-Bresler, Mikkael A. Sekeres, H. Joachim Deeg, Consuelo Del Cañizo, Peter L. Greenberg, Jamile M. Shammo, Barry Skikne, Xujie Yu, Alan F. List

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Background: Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed. Methods: We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS patients with del(5q) from two multicenter trials. Results: A total of 33.9, 34.3, and 31.8% patients were aged <65 years, ≥65 to <75 years, and ≥75 years, respectively. Age <65 years was associated with less favorable International Prognostic Scoring System (IPSS) risk and additional cytopenias at baseline versus older age groups, significantly lower cytogenetic response rates (p = 0.022 vs. ≥65 to <75 years; p = 0.047 vs. ≥75 years), and higher rates of acute myeloid leukemia (AML) progression (Gray's test, p = 0.013). Lenalidomide was equally well tolerated across age groups, producing consistently high rates of red blood cell transfusion independence ≥26 weeks. Conclusions: Baseline disease characteristics and AML progression appear to be more severe in younger lower-risk MDS patients with del(5q), whereas older age does not seem to compromise the response to lenalidomide. Trial registration: ClinicalTrials.gov NCT00065156 and NCT00179621

Original languageEnglish (US)
Article number131
JournalJournal of Hematology and Oncology
Volume10
Issue number1
DOIs
StatePublished - Jun 26 2017

Keywords

  • Acute myeloid leukemia
  • Age
  • Lenalidomide
  • Myelodysplastic syndromes
  • del(5q)

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)'. Together they form a unique fingerprint.

  • Cite this

    Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mittelman, M., Muus, P., Nimer, S. D., Hellström-Lindberg, E., Powell, B. L., Guerci-Bresler, A., Sekeres, M. A., Deeg, H. J., Del Cañizo, C., Greenberg, P. L., Shammo, J. M., Skikne, B., Yu, X., & List, A. F. (2017). Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). Journal of Hematology and Oncology, 10(1), [131]. https://doi.org/10.1186/s13045-017-0491-2